Cargando…

Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy

Despite a generally better prognosis than high-grade glioma (HGG), recurrence and malignant progression are the main causes for the poor prognosis and difficulties in the treatment of low-grade glioma (LGG). It is of great importance to learn about the risk factors and underlying mechanisms of LGG r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teng, Chubei, Zhu, Yongwei, Li, Yueshuo, Dai, Luohuan, Pan, Zhouyang, Wanggou, Siyi, Li, Xuejun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168984/ https://www.ncbi.nlm.nih.gov/pubmed/35677036 http://dx.doi.org/10.3389/fimmu.2022.899710

Ejemplares similares

Functional characterization of TSPAN7 as a novel indicator for immunotherapy in glioma
por: Chen, Long, et al.
Publicado: (2023)

Identification of the novel prognostic biomarker, MLLT11, reveals its relationship with immune checkpoint markers in glioma
por: Chen, Long, et al.
Publicado: (2022)

Immune Infiltration Associated MAN2B1 Is a Novel Prognostic Biomarker for Glioma
por: Lin, Xuelei, et al.
Publicado: (2022)

Transcription factor ZBTB42 is a novel prognostic factor associated with immune cell infiltration in glioma
por: Li, Yanwen, et al.
Publicado: (2023)

Combination of Immunotherapy and Radiotherapy for Recurrent Malignant Gliomas: Results From a Prospective Study
por: Jiang, Haihui, et al.
Publicado: (2021)

Survival Risk Prediction Models of Gliomas Based on IDH and 1p/19q
por: Zou, Han, et al.
Publicado: (2020)

Alternations and Applications of the Structural and Functional Connectome in Gliomas: A Mini-Review
por: Chen, Ziyan, et al.
Publicado: (2022)

Overexpression of mitochondrial serine hydroxyl-methyltransferase 2 is associated with poor prognosis and promotes cell proliferation and invasion in gliomas
por: Wu, Ming, et al.
Publicado: (2017)

Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy
por: Chuntova, Pavlina, et al.
Publicado: (2019)

miR-526b-3p serves as a prognostic factor and regulates the proliferation, invasion, and migration of glioma through targeting WEE1
por: Wu, Ming, et al.
Publicado: (2019)

Integration of single-cell regulon atlas and multi-omics data for prognostic stratification and personalized treatment prediction in human lung adenocarcinoma
por: Xiong, Yi, et al.
Publicado: (2023)

Classification related to immunogenic cell death predicts prognosis, immune microenvironment characteristics, and response to immunotherapy in lower-grade gliomas
por: Kuang, Yirui, et al.
Publicado: (2023)

DNA Damage Response Evaluation Provides Novel Insights for Personalized Immunotherapy in Glioma
por: Chen, Mu, et al.
Publicado: (2022)

SAMD9 Is Relating With M2 Macrophage and Remarkable Malignancy Characters in Low-Grade Glioma
por: Ma, Wenping, et al.
Publicado: (2021)

Classification of Gliomas and Germinomas of the Basal Ganglia by Transfer Learning
por: Ye, Ningrong, et al.
Publicado: (2022)

PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma
por: Zhi, Wenqian, et al.
Publicado: (2023)

Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas
por: Zeng, Jiayi, et al.
Publicado: (2021)

Immunotherapy for malignant glioma
por: Suryadevara, Carter M., et al.
Publicado: (2015)

Immunotherapies for Malignant Glioma
por: Boussiotis, Vassiliki A., et al.
Publicado: (2017)

DDOST Correlated with Malignancies and Immune Microenvironment in Gliomas
por: Chang, Xiaojing, et al.
Publicado: (2022)

Efficacy and safety of innate and adaptive immunotherapy combined with standard of care in high-grade gliomas: a systematic review and meta-analysis
por: Guo, Baofeng, et al.
Publicado: (2023)

An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas
por: Zhang, Hongbo, et al.
Publicado: (2020)

Six Immune Associated Genes Construct Prognostic Model Evaluate Low-Grade Glioma
por: Tan, Yin Qiu, et al.
Publicado: (2020)

Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma
por: Yan, Dongming, et al.
Publicado: (2022)

Immunotherapy: a promising approach for glioma treatment
por: Yasinjan, Feroza, et al.
Publicado: (2023)

Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress
por: Perrino, Matteo, et al.
Publicado: (2023)

IGFBP2 from a novel copper metabolism-associated biomarker promoted glioma progression and response to immunotherapy
por: Luo, Qisheng, et al.
Publicado: (2023)

Mood swings are causally associated with intracranial aneurysm subarachnoid hemorrhage: A Mendelian randomization study
por: Peng, Kang, et al.
Publicado: (2023)

Deciphering the role of QPCTL in glioma progression and cancer immunotherapy
por: Liu, Yu’e, et al.
Publicado: (2023)

Pre-clinical models for evaluating glioma targeted immunotherapies
por: Frederico, Stephen C., et al.
Publicado: (2023)

Editorial: Novel biomarkers for predicting response to cancer immunotherapy
por: Huangfu, Shuchen, et al.
Publicado: (2023)

Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas
por: Li, Yang, et al.
Publicado: (2023)

EVA1C Is a Potential Prognostic Biomarker and Correlated With Immune Infiltration Levels in WHO Grade II/III Glioma
por: Hu, Zhicheng, et al.
Publicado: (2021)

Prognostic Gene Expression Signature in Patients With Distinct Glioma Grades
por: Ait Ssi, Saadia, et al.
Publicado: (2021)

Multi-dimensional omics characterization in glioblastoma identifies the purity-associated pattern and prognostic gene signatures
por: Xiong, Yi, et al.
Publicado: (2020)

Antigen Presentation Machinery Signature-Derived CALR Mediates Migration, Polarization of Macrophages in Glioma and Predicts Immunotherapy Response
por: Chen, Rui, et al.
Publicado: (2022)

Optimization of cancer immunotherapy through pyroptosis: A pyroptosis-related signature predicts survival benefit and potential synergy for immunotherapy in glioma
por: Zeng, Yu, et al.
Publicado: (2022)

Prognostic value of γ‐aminobutyric acidergic synapse-associated signature for lower-grade gliomas
por: Jiang, Hongxiang, et al.
Publicado: (2022)

Biomarkers for immunotherapy in esophageal cancer
por: Wang, Xuelian, et al.
Publicado: (2023)

Glioma Stem Cells and Immunotherapy for the Treatment of Malignant Gliomas
por: Toda, Masahiro
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5ork4dd22vabsgaehd8brdc63v